Clinical management of metastatic colorectal cancer in the era of precision medicine

F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Comprehensive review of targeted therapy for colorectal cancer

YH **e, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

A Cervantes, R Adam, S Roselló, D Arnold… - Annals of …, 2023 - annalsofoncology.org
Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial

D Morton, M Seymour, L Magill, K Handley… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard
postoperative chemotherapy for locally advanced colon cancer but requires formal …

Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology

AB Benson, AP Venook, M Adam, G Chang… - Journal of the National …, 2024 - jnccn.org
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second
leading cause of cancer death in the United States. Management of disseminated metastatic …

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 …

W Li, C Zhou, L Yu, Z Hou, H Liu, L Kong, Y Xu, J He… - Autophagy, 2024 - Taylor & Francis
Bevacizumab plays an important role in the first and second line treatment for metastatic
colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an …

Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology

AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2021 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Precision oncology in metastatic colorectal cancer—from biology to medicine

F Di Nicolantonio, PP Vitiello, S Marsoni… - Nature reviews Clinical …, 2021 - nature.com
Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Pathological features and prognostication in colorectal cancer

K Chen, G Collins, H Wang, JWT Toh - Current Oncology, 2021 - mdpi.com
The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined
by the Union for International Cancer Control (UICC) and American Joint Committee on …

Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of …

S Piawah, AP Venook - Cancer, 2019 - Wiley Online Library
Despite recent advances in the management of colorectal cancer, metastatic disease
remains challenging, and patients are rarely cured. However, a better understanding of the …